Akebia Therapeutics Inc

Overview

Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company's product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. The company works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company has its operations in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US
Key Stats
Address
245 1st St, CAMBRIDGE, Massachusetts
Headquarters

United States of America

Contact

1 617 8712098

Website
akebia.com
No of Employees

380

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

AKBA [NASD]

Revenue (2020)

$295 m

-11.9% (2020 vs 2019)
Net Income (2020)

$-383 m

-37% (2020 vs 2019)
Net Profit Margin

-130 %

-55.6% (2020 vs 2019)
Market Cap *

$513 m

EPS *

$-2.8

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Akebia Therapeutics IncArdelyx IncChinook Therapeutics IncAdvantagene Inc
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City CAMBRIDGE FREMONT SEATTLE NEEDHAM
Headquarter State/Province Massachusetts California Washington Massachusetts
No. of Employees 380 129 105 50
Entity Type Public Public Public Public

Products & Services

Akebia Therapeutics develops bio pharmaceutical therapeutics based on hypoxia inducible factor (HIF). The key products under development offered by the company include the following

Products
  • Pipeline Products
  • Hypoxia Inducible Factor Candidates:
  • Vadadustat (AKB-6548):
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In June, the company and Cyclerion Therapeutics entered into a global license agreement for the…
2021 New Product Approvals In March, the company and its collaboration partner, Japan Tobacco secured approval from the Pharmaceuticals…
2020 Contracts/Agreements In July, the company and the University of Texas Health Science Center at Houston entered…
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Keryx Biopharmaceuticals Inc

Address

One Marina Park Drive, Twelfth Floor, Boston
United States of America

Telephone

1 617 4663500

Website

www.keryx.com
AOI Pharmaceuticals Inc

Address

20Th Floor, 750 Lexington Avenue, New York City
United States of America

Telephone

1 212 5315965

Website

www.keryx.com
ACCESS Oncology Inc

Address

Ninth Floor, 730 Fifth Avenue, New York City
United States of America

Telephone

1 212 3338681

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
04 Jun 2021 Akebia Therapeutics Enters into Licensing Agreement with Cyclerion Therapeutics Licensing Agreement Akebia Therapeutics Inc Cyclerion Therapeutics Inc
25 Feb 2021 HealthCare Royalty to Acquire Rights to Receive Royalties and Sales Milestones on Vadadustat from Akebia Therapeutics Asset Transaction Akebia Therapeutics Inc; Healthcare Royalty Management LLC
14 Jul 2020 Akebia Therapeutics and University of Texas Health Science Center at Houston Enter into Partnership for ARDS in COVID-19 Patients Partnership Akebia Therapeutics Inc; University of Texas Health Science Center at Houston
11 May 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
02 Apr 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
12 Mar 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

40

Active Jobs

23

Posted

27

Closed

Job Trends

Latest Jobs

Job title Company Country
Director QA Stability Akebia Therapeutics Inc United States
Manager, Quality Metrics & Annual Product Review Akebia Therapeutics Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar